Image pharmaphorum Editor R&D 2021: the year mRNA therapeutics came of age It started with two Covid-19 vaccines – 2021 is the year interest in mRNA therapeutics boomed, reports Katrina Megget Patients From patient engagement to patient centricity Words matter. In the pharma industry, “patient engagement” and “patient centricity” might seem like interchangeable bits of corporate jargon. Digital Digital health innovation in 2022: Anticipating healthcare t... We spoke with Tanja Dowe, ahead of the annual J.P. Sales & Marketing Seizing opportunities with perfectly pitched messages Personal relationships have been the dominant force in sales for generations but the pandemic has ripped up this conveyer belt of convenience. Load more results
R&D 2021: the year mRNA therapeutics came of age It started with two Covid-19 vaccines – 2021 is the year interest in mRNA therapeutics boomed, reports Katrina Megget
Patients From patient engagement to patient centricity Words matter. In the pharma industry, “patient engagement” and “patient centricity” might seem like interchangeable bits of corporate jargon.
Digital Digital health innovation in 2022: Anticipating healthcare t... We spoke with Tanja Dowe, ahead of the annual J.P.
Sales & Marketing Seizing opportunities with perfectly pitched messages Personal relationships have been the dominant force in sales for generations but the pandemic has ripped up this conveyer belt of convenience.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.